Sallman, D., Malki, M. A., Asch, A., Wang, E., Jurcic, J., Bradley, T., Flinn, I., Pollyea, D., Kambhampati, S., Tanaka, T., Zeidner, J., Garcia-Manero, G., Jeyakumar, D., Gu, L., Tan, A., Chao, M., O’Hear, C., Lal, I., Vyas, P., & Daver, N. (2022). MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results. Clinical Lymphoma Myeloma and Leukemia, 22, S314–S315. https://doi.org/10.1016/s2152-2650(22)01415-x